Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer
NL-OMON54643Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of niraparib in prostate cancer (PCa) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Radiographic progression-free survival. Started Aug 2019; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON54643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54643.